EyePoint Shares Crash After Duravyu Phase 3 Stumble in Wet AMD, But Treatment Burden Reduction Shines
EyePoint Pharmaceuticals' (EYPT) shares plunged roughly 67–71% on August 17, 2026, after Duravyu missed the primary endpoint in the LUGANO Phase 3 trial for wet AMD, failing to show non‑inferiority to aflibercept (Eylea) in best‑corrected visual acuity (BCVA) in the full population.
The company attributed the miss to vision loss in 9 of 211 Duravyu patients unrelated to wet AMD; in an unplanned (ad hoc) analysis excluding these patients, Duravyu did meet non‑inferiority (p=0.0096).
Despite the primary endpoint failure, Duravyu reduced treatment burden by ~42% versus aflibercept through Week 56 and showed a favorable safety profile and high supplement‑free rates, positions that some analysts say still support further development pending the second Phase 3 (LUCIA) readout in late 2026.
Sources:
EyePoint phase 3 for AMD disappoints, tanking stock - Fierce Pharma
EyePoint's Phase 3 fail sends stock spiraling amid next-gen AMD race
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
EyePoint Shares Plunge 69% After DURAVYU Phase 3 Trial Misses ...
Eyepoint study results for vision treatment disappoint, but ...
EyePoint (EYPT) Is Down 62.7% After DURAVYU Misses Phase 3 ...
EyePoint shares plunge as DURAVYU misses primary endpoint By Investing.com
EyePoint’s DURAVYU Misses Primary Endpoint in Phase III Wet AMD Trial
EyePoint's Duravyu falls short to Eylea in Phase III trial
EYPT Stock On Track To Hit 16-Month Lows After Wet AMD ...
EyePoint Misses Primary Goal in Phase 3 Wet AMD Trial of Duravyu; Shares Drop Pre-Bell
EyePoint Stock Crashes On Surprise Flop In Final-Phase Eye Drug ...